TGTX Total Stockholder Equity vs Long Term Debt Analysis

TGTX Stock  USD 31.67  1.17  3.56%   
TG Therapeutics financial indicator trend analysis is much more than just breaking down TG Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether TG Therapeutics is a good investment. Please check the relationship between TG Therapeutics Total Stockholder Equity and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of TG Therapeutics Total Stockholder Equity account and Long Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between TG Therapeutics' Total Stockholder Equity and Long Term Debt is -0.37. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of TG Therapeutics, assuming nothing else is changed. The correlation between historical values of TG Therapeutics' Total Stockholder Equity and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of TG Therapeutics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Stockholder Equity i.e., TG Therapeutics' Total Stockholder Equity and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.37
Relationship DirectionNegative 
Relationship StrengthInsignificant

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Long Term Debt

Long-term debt is a debt that TG Therapeutics has held for over one year. Long-term debt appears on TG Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on TG Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from TG Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into TG Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.At this time, TG Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 409.5 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 39.6 M in 2024.

TG Therapeutics fundamental ratios Correlations

0.720.82-0.030.8-0.74-0.750.880.470.980.790.820.690.821.0-0.230.390.570.770.52-0.11-0.080.410.760.680.59
0.720.6-0.440.66-0.58-0.620.70.790.730.610.660.50.650.69-0.150.130.490.860.020.010.020.130.780.560.19
0.820.6-0.320.96-0.56-0.80.710.470.80.840.680.730.960.82-0.280.280.610.640.7-0.13-0.110.30.80.680.53
-0.03-0.44-0.32-0.48-0.070.44-0.06-0.69-0.06-0.34-0.26-0.29-0.440.020.080.22-0.37-0.41-0.02-0.06-0.050.23-0.34-0.360.09
0.80.660.96-0.48-0.48-0.870.670.560.780.870.750.741.00.79-0.250.30.710.740.64-0.05-0.030.320.820.780.55
-0.74-0.58-0.56-0.07-0.480.21-0.96-0.35-0.85-0.27-0.33-0.16-0.44-0.750.130.270.09-0.31-0.130.030.050.25-0.5-0.060.05
-0.75-0.62-0.80.44-0.870.21-0.46-0.54-0.66-0.98-0.94-0.85-0.9-0.740.26-0.6-0.92-0.88-0.70.090.05-0.6-0.77-0.95-0.79
0.880.70.71-0.060.67-0.96-0.460.470.960.490.550.370.640.88-0.17-0.070.180.530.27-0.03-0.04-0.050.650.320.16
0.470.790.47-0.690.56-0.35-0.540.470.50.520.510.530.530.42-0.12-0.060.410.68-0.01-0.08-0.09-0.070.520.460.06
0.980.730.8-0.060.78-0.85-0.660.960.50.70.740.590.770.98-0.220.20.430.690.44-0.09-0.070.220.730.550.44
0.790.610.84-0.340.87-0.27-0.980.490.520.70.920.910.90.78-0.350.60.890.840.75-0.24-0.20.610.780.90.82
0.820.660.68-0.260.75-0.33-0.940.550.510.740.920.780.790.81-0.240.60.850.910.62-0.09-0.050.610.760.880.78
0.690.50.73-0.290.74-0.16-0.850.370.530.590.910.780.780.67-0.380.60.80.730.64-0.36-0.320.610.610.810.79
0.820.650.96-0.441.0-0.44-0.90.640.530.770.90.790.780.8-0.250.390.760.770.67-0.06-0.030.40.820.830.62
1.00.690.820.020.79-0.75-0.740.880.420.980.780.810.670.8-0.230.40.560.740.54-0.1-0.070.420.740.670.61
-0.23-0.15-0.280.08-0.250.130.26-0.17-0.12-0.22-0.35-0.24-0.38-0.25-0.23-0.1-0.17-0.18-0.290.360.36-0.11-0.34-0.16-0.23
0.390.130.280.220.30.27-0.6-0.07-0.060.20.60.60.60.390.4-0.10.80.550.48-0.080.01.00.290.760.91
0.570.490.61-0.370.710.09-0.920.180.410.430.890.850.80.760.56-0.170.80.840.59-0.06-0.010.80.60.980.85
0.770.860.64-0.410.74-0.31-0.880.530.680.690.840.910.730.770.74-0.180.550.840.33-0.010.030.550.780.880.62
0.520.020.7-0.020.64-0.13-0.70.27-0.010.440.750.620.640.670.54-0.290.480.590.33-0.22-0.190.50.490.580.76
-0.110.01-0.13-0.06-0.050.030.09-0.03-0.08-0.09-0.24-0.09-0.36-0.06-0.10.36-0.08-0.06-0.01-0.221.0-0.080.1-0.03-0.18
-0.080.02-0.11-0.05-0.030.050.05-0.04-0.09-0.07-0.2-0.05-0.32-0.03-0.070.360.0-0.010.03-0.191.0-0.010.120.03-0.11
0.410.130.30.230.320.25-0.6-0.05-0.070.220.610.610.610.40.42-0.111.00.80.550.5-0.08-0.010.290.760.92
0.760.780.8-0.340.82-0.5-0.770.650.520.730.780.760.610.820.74-0.340.290.60.780.490.10.120.290.650.46
0.680.560.68-0.360.78-0.06-0.950.320.460.550.90.880.810.830.67-0.160.760.980.880.58-0.030.030.760.650.84
0.590.190.530.090.550.05-0.790.160.060.440.820.780.790.620.61-0.230.910.850.620.76-0.18-0.110.920.460.84
Click cells to compare fundamentals

TG Therapeutics Account Relationship Matchups

TG Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets163.0M625.6M379.6M193.6M329.6M346.1M
Other Current Liab5.4M26.7M61.5M8.0M13.5M14.2M
Total Current Liabilities84.4M87.6M65.4M53.2M53.7M56.4M
Total Stockholder Equity(701.2M)519.4M(1.3B)(1.5B)160.5M168.5M
Property Plant And Equipment Net11.8M11.8M11.1M10.8M8.1M8.6M
Net Debt(71.8M)(511.5M)(219.8M)(19.2M)17.9M18.8M
Retained Earnings(701.2M)(980.6M)(1.3B)(1.5B)(1.5B)(1.4B)
Cash112.6M553.4M298.9M102.3M92.9M59.3M
Non Current Assets Total13.9M13.9M48.7M25.3M11.6M7.5M
Cash And Short Term Investments140.4M605.4M350.3M174.1M217.5M228.4M
Common Stock Shares Outstanding88.4M115.3M132.2M135.4M148.5M155.9M
Liabilities And Stockholders Equity(576.8M)625.6M(1.2B)(1.4B)329.6M346.1M
Other Stockholder Equity(109K)1.5B1.6B1.6B1.7B1.8B
Total Liab124.4M106.3M142.5M135.0M169.1M177.5M
Property Plant And Equipment Gross11.8M11.8M11.1M10.8M9.6M10.0M
Total Current Assets149.2M611.7M331.0M168.3M317.9M333.8M
Non Currrent Assets Other1.3M1.3M1.3M1.3M1.4M1.3M
Net Receivables108.5K95K0.01.4M51.1M53.6M
Non Current Liabilities Total40.0M18.7M77.1M81.8M115.4M121.1M
Other Current Assets611K6.3M14.8M6.6M9.5M10.0M
Accounts Payable30.0M37.0M(457K)42.0M38.5M40.4M
Common Stock Total Equity109K141K143K146K131.4K74.7K
Common Stock109K141K143K146K151K105.2K
Other Assets3.4M13.1M3.1M2.9M329.6M346.1M
Property Plant Equipment282K481K600K307K353.1K370.7K
Short Long Term Debt Total40.8M42.0M79.0M83.1M110.8M116.3M
Short Term Investments27.8M52.0M15.9M59.4M124.6M130.8M
Other Liab762K610K457K305K274.5K260.8K
Short Term Debt1.6M23.8M3.8M3.2M1.4M2.8M
Net Tangible Assets37.8M518.6M310.7M57.8M66.5M118.5M
Retained Earnings Total Equity(701.2M)(980.6M)(1.3B)(1.5B)(1.4B)(1.3B)
Capital Surpluse740.0M1.5B1.6B1.6B1.8B1.9B
Deferred Long Term Liab762K610K457K305K274.5K260.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.